Xolair loss of exclusivity?

Are you asking about Xolair (omalizumab) losing exclusivity in a particular market (US, EU, etc.) and/or about patent vs regulatory data exclusivity?

High-level summary:
- Xolair is a biologic, so “loss of exclusivity” can mean several protections at once: patent protection (composition, manufacturing, uses), and regulatory data exclusivity that blocks biosimilar approval for a period after launch.
- In the US, the Biologics Price Competition and Innovation Act provides 12 years of data exclusivity for a new biologic from initial approval. Omalizumab was approved in 2003, so data exclusivity would have run (or largely run) by around 2015, but actual biosimilar entry also depends on patent status and litigation.
- There are multiple patents around omalizumab (not just the core composition patent). Some may have expired, others may still provide protection in certain jurisdictions or for certain claims (manufacturing methods, formulations, uses). This can delay or limit biosimilar entry even after data exclusivity ends.
- In the EU and other regions, data exclusivity and market protection timelines differ; some markets have seen biosimilar olamizumab competition start later due to patent protections or regulatory hurdles.

If you want, tell me the country/region and whether you’re focused on patent expiry dates or regulatory data exclusivity. I can give you a concise, current status for that market and any known biosimilar approvals or litigation that might affect Xolair’s exclusivity.